Go Pro
→ The ultimate IPO unicorn before Labor Day (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$1.32
+1.5%		$3.36
$1.07
▼
$71.50
$2.20M0.7258,722 shs19,068 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.58
+1.3%		$1.70
$1.47
▼
$6.03
$8.75M1.9852,127 shs34,009 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.23
-8.2%		$0.36
$0.08
▼
$0.91
$7.90M0.56.55 million shs442,599 shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$4.67
+0.9%		$3.15
$1.90
▼
$13.93
$10.61M2.2372,062 shs79,153 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
+7.88%-58.60%-61.19%-60.96%-94.68%
Imunon, Inc. stock logo
IMNN
Imunon
0.00%-2.50%-6.59%-24.27%-72.77%
OSR Holdings, Inc. stock logo
OSRH
OSR
-24.62%+44.12%-46.85%-36.86%-59.20%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
+8.94%+16.62%+64.77%+49.84%+52.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$1.32
+1.5%		$3.36
$1.07
▼
$71.50
$2.20M0.7258,722 shs19,068 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.58
+1.3%		$1.70
$1.47
▼
$6.03
$8.75M1.9852,127 shs34,009 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.23
-8.2%		$0.36
$0.08
▼
$0.91
$7.90M0.56.55 million shs442,599 shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$4.67
+0.9%		$3.15
$1.90
▼
$13.93
$10.61M2.2372,062 shs79,153 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
+7.88%-58.60%-61.19%-60.96%-94.68%
Imunon, Inc. stock logo
IMNN
Imunon
0.00%-2.50%-6.59%-24.27%-72.77%
OSR Holdings, Inc. stock logo
OSRH
OSR
-24.62%+44.12%-46.85%-36.86%-59.20%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
+8.94%+16.62%+64.77%+49.84%+52.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
2.00
Hold$200.0015,051.52% Upside
Imunon, Inc. stock logo
IMNN
Imunon
2.00
Hold$10.00532.91% Upside
OSR Holdings, Inc. stock logo
OSRH
OSR
1.00
SellN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BCAB, XBIO, OSRH, and IMNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
BioAtla, Inc. stock logo
BCAB
BioAtla
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Imunon, Inc. stock logo
IMNN
Imunon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
OSR Holdings, Inc. stock logo
OSRH
OSR
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$8.50M0.26N/AN/A($28.51) per share-0.05
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/A$0.35 per shareN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
$1.81M4.37N/AN/A$3.56 per share0.06
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.98M3.59N/AN/A$2.65 per share1.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$59.61M-$25.45N/AN/AN/AN/AN/A-289.67%11/12/2026 (Estimated)
Imunon, Inc. stock logo
IMNN
Imunon
-$14.49M-$3.83N/AN/AN/AN/A-358.01%-132.91%11/12/2026 (Estimated)
OSR Holdings, Inc. stock logo
OSRH
OSR
-$27.06M-$0.37N/AN/AN/A-593.15%-8.36%-6.24%N/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$2.68M-$1.16N/AN/AN/A-75.90%-40.62%-34.97%11/6/2026 (Estimated)

Latest BCAB, XBIO, OSRH, and IMNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$0.02N/A-$0.02N/A$0.32 million
8/13/2026Q2 2026
BioAtla, Inc. stock logo
BCAB
BioAtla
-$8.50$0.14+$8.64$0.27$6.50 million$6.50 million
8/11/2026Q2 2026
Imunon, Inc. stock logo
IMNN
Imunon
-$0.8675-$0.54+$0.3275-$0.54N/AN/A
8/6/2026Q2 2026
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A-$0.41N/A-$0.41N/A$0.66 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
0.20
0.20
Imunon, Inc. stock logo
IMNN
Imunon
2.86
1.82
1.82
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A
0.18
0.14
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
7.43
7.43

Institutional Ownership

CompanyInstitutional Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
9.34%
Imunon, Inc. stock logo
IMNN
Imunon
2.83%
OSR Holdings, Inc. stock logo
OSRH
OSR
36.90%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
601.67 million1.51 millionOptionable
Imunon, Inc. stock logo
IMNN
Imunon
305.61 million5.45 millionNot Optionable
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A35.12 million22.16 millionN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
42.29 million2.12 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest
August 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30986685
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
August 7, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...
June 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/xenetic-biosciences-inc-announces-collaboration-124000825.html
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 4, 2026  |  accessnewswire.comA
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026  |  accessnewswire.comA
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026  |  accessnewswire.comA
Xenetic Biosciences: Q1 Earnings Snapshot
May 12, 2026  |  wtop.comW
Xenetic Biosciences Grants Equity Award to Interim CEO
April 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XBIO/pressreleases/1520659/xenetic-biosciences-grants-equity-award-to-interim-ceo/
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 22, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 11, 2025  |  accessnewswire.comA
Xenetic extends R&D collaboration with The Scripps Research Institute
November 19, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/xenetic-extends-r-d-collaboration-with-the-scripps-research-institute/ar-AA1QKDxC
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
November 19, 2025  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 13, 2025  |  accessnewswire.comA
Xenetic Biosciences Announces Public Offering Pricing
October 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/xenetic-biosciences-announces-public-offering-pricing/ar-AA1Ossgk
Xenetic 735,000 share Spot Secondary priced at $6.12
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/xenetic-735000-share-spot-secondary-priced-at-612/ar-AA1Oeziy
Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges
October 10, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/10/48161813/micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
August 13, 2025  |  accessnewswire.comA
Xenetic Biosciences Reports Improved Financial Performance
August 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/xenetic-biosciences-reports-improved-financial-performance/ar-AA1KqObx

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$1.32 +0.02 (+1.54%)
As of 03:59 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Imunon stock logo

Imunon NASDAQ:IMNN

$1.58 +0.02 (+1.28%)
As of 04:00 PM Eastern

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

OSR stock logo

OSR NASDAQ:OSRH

$0.22 -0.02 (-8.16%)
As of 03:58 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$4.67 +0.04 (+0.86%)
As of 04:00 PM Eastern

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas